Brett L. Carlson

5.1k citations

69 papers · 3.6k indexed · h-index 29

Genetics top 0.5%
- Glioma Diagnosis and Treatment 46
Cancer Research top 2%
Oncology top 2%
- Cancer-related Molecular Pathways 10
- PARP inhibition in cancer therapy 9
Molecular Biology top 5%
- DNA Repair Mechanisms 12
Cell Biology top 5%
- Microtubule and mitosis dynamics 6
Pulmonary and Respiratory Medicine
- Brain Metastases and Treatment 10
- Lung Cancer Treatments and Mutations 7
Biotechnology
- Cancer Research and Treatments 9

Co-authors: Jann N. Sarkaria Mark A. Schroeder C. David James Paul A. Decker Gaspar J. Kitange Wenting Wu Caterina Giannini Ann C. Mladek
Cited by: Genetics Cancer Research Oncology
Journals: Neuro-Oncology (9 papers)Clinical Cancer Research (8 papers)Cancer Research (8 papers)
Partner nations: United States United Kingdom China

In The Last Decade

Brett L. Carlson

67 papers receiving 3.6k citations

Peers

Countries citing papers authored by Brett L. Carlson

Since Specialization

Citations

This map shows the geographic impact of Brett L. Carlson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brett L. Carlson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brett L. Carlson more than expected).

Fields of papers citing papers by Brett L. Carlson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brett L. Carlson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brett L. Carlson. The network helps show where Brett L. Carlson may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Brett L. Carlson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Brett L. Carlson Line = papers co-authored together Brett L. Carlson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors Neuro-Oncology ·Wenjuan Zhang,Michael P. Grams,Rajneet K. Oberoi,Ju‐Hee Oh,Paul A. Decker,Terence T. Sio,Surabhi Talele,Zena Wilson,Mehmet Sait Berhuni,Katrina K. Bakken,Brett L. Carlson,Jesús J. Marrero-Centeno,Danielle M. Burgenske,E. Tryggestad,Deng Hong-wu,William F. Elmquist,Jann N. Sarkaria	2025	1
2	Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization Science Translational Medicine ·松本伯夫,Daniel J. Laverty,Surabhi Talele,伸一宮森,Brett L. Carlson,M.N. Zapotochnaya,Katrina K. Bakken,Danielle M. Burgenske,Paul A. Decker,Rachael A. Vaubel,Jeanette E. Eckel‐Passow,Rohit Bhargava,Zhenkun Lou,Petra Hamerlik,Brendan A.C. Harley,William F. Elmquist,Zachary D. Nagel,Shiv K. Gupta,Jann N. Sarkaria	2024	14
3	Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628 Molecular Cancer Therapeutics ·Florencia María Rembado,Sneha Rathi,Mehmet Sait Berhuni,Michael P. Grams,Rachael A. Vaubel,Katrina K. Bakken,Jesús J. Marrero-Centeno,Brett L. Carlson,Raivo Ranne,Paul A. Decker,Jeanette E. Eckel‐Passow,Danielle M. Burgenske,Uwimana Lambert,Joshua D. Trzasko,Francsico R Hung,William F. Elmquist,Nicholas B. Remmes,Jann N. Sarkaria	2024	0
4	Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models Clinical Cancer Research ·Sonia Jain,Jessica I. Griffith,M.N. Zapotochnaya,Sneha Rathi,S. Mitterer,Dennis R. Louie,Paul A. Decker,Shiv K. Gupta,Raivo Ranne,Brett L. Carlson,Katrina K. Bakken,Danielle M. Burgenske,Matt Reingold,高徳岩永,Rachael A. Vaubel,Jeanette E. Eckel‐Passow,Edward B. Reilly,William F. Elmquist,Jann N. Sarkaria	2024	9
5	WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models Neuro-Oncology Advances ·D. Steffy,Sylwia A. Stopka,Ju‐Hee Oh,Ann C. Mladek,Danielle M. Burgenske,Michael S. Regan,Gerard Baquer,Paul A. Decker,Brett L. Carlson,Katrina K. Bakken,Jinqiang Zhang,Lily Liu,Mekdelawit Wondiyfraw,Ariela Torres Cruz,Wei Zhong,Nhan L. Tran,William F. Elmquist,Nathalie Y.R. Agar,Jann N. Sarkaria,Forest M. White	2023	4
6	In Vivo Efficacy of Tesevatinib in EGFR -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling Molecular Cancer Therapeutics ·Sani H. Kizilbash,Shiv K. Gupta,Karen E. Parrish,Janice K. Laramy,Minjee Kim,Gautham Gampa,Brett L. Carlson,Katrina K. Bakken,Ann C. Mladek,Mark A. Schroeder,Paul A. Decker,William F. Elmquist,Jann N. Sarkaria	2021	10
7	Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma Molecular Cancer Therapeutics ·Sani H. Kizilbash,Shiv K. Gupta,Kenneth Tou En Chang,Carol A. Mancuso Nichols,Karen E. Parrish,Brett L. Carlson,Katrina K. Bakken,Ann C. Mladek,Mark A. Schroeder,Paul A. Decker,Gaspar J. Kitange,Yuqiao Shen,Ying Feng,Andrew A. Protter,William F. Elmquist,Jann N. Sarkaria	2017	60
8	CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma Clinical Cancer Research ·Tony Avril,Amandine Etcheverry,Raphaël Pineau,Joanna Obacz,Gwénaële Jégou,Florence Jouan,Pierre‐Jean Le Reste,Masumeh Hatami,Rivka R. Colen,Brett L. Carlson,Paul A. Decker,Jann N. Sarkaria,Élodie Vauléon,F. Ducastelle,Anne Clavreul,Jean Mosser,Éric Chevet,Véronique Quillien	2017	34
9	The Selective ATR Inhibitor VX-970 Enhances the Therapeutic Effects of Radiation Therapy in Triple Negative Breast Cancer Patient-Derived Xenografts and is a Novel Strategy to Overcome Therapeutic Resistance International Journal of Radiation OncologyBiologyPhysics ·Robert W. Mutter,فرناز نظرزاده عنصرودی,Mohamed M. Kahila,Xiaolin Yu,Mark A. Schroeder,Brett L. Carlson,Bahriddinova Ismigul Ilhomiddin qizi,Virginia W. Hayes,Bethany Logan,Jann N. Sarkaria,Zhenkun Lou	2017	2
10	Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins Cell Reports ·Gaspar J. Kitange,Ann C. Mladek,Mark A. Schroeder,Young-Loveridge Jennifer M,Brett L. Carlson,Yuji Zhang,Asha Nair,Jeong‐Heon Lee,Huihuang Yan,Paul A. Decker,Zhiguo Zhang,Jann N. Sarkaria	2016	53
11	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System Molecular Cancer Therapeutics ·Karen E. Parrish,Ling Cen,J. C. Murray,David Calligaris,Sani H. Kizilbash,Rajendar K. Mittapalli,Brett L. Carlson,Mark A. Schroeder,Julieann Sludden,Alan V. Boddy,Nathalie Y.R. Agar,Nicola J. Curtin,William F. Elmquist,Jann N. Sarkaria	2015	66
12	The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma Clinical Cancer Research ·Jenny L. Pokorny,David Calligaris,Shiv K. Gupta,高汝熹,Kyle J. Sloan,Katrina K. Bakken,Brett L. Carlson,Mark A. Schroeder,Debra L. Evans,Zhenkun Lou,Paul A. Decker,Jeanette E. Eckel‐Passow,Vincenzo Pucci,Bennett Ma,Stuart D. Shumway,William F. Elmquist,Nathalie Y.R. Agar,Jann N. Sarkaria	2015	71
13	Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma JNCI Journal of the National Cancer Institute ·Shiv K. Gupta,Sani H. Kizilbash,Brett L. Carlson,Ann C. Mladek,Felix Boakye‐Agyeman,Katrina K. Bakken,Jenny L. Pokorny,Mark A. Schroeder,Paul A. Decker,Ling Cen,Jeanette E. Eckel‐Passow,Gobinda Sarkar,Karla V. Ballman,Joel M. Reid,Robert B. Jenkins,Roeland Verhaak,Erik P. Sulman,Gaspar J. Kitange,Jann N. Sarkaria	2015	93
14	Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts Clinical Cancer Research ·Shiv K. Gupta,Ann C. Mladek,Brett L. Carlson,Felix Boakye‐Agyeman,Katrina K. Bakken,Sani H. Kizilbash,Mark A. Schroeder,Joel M. Reid,Jann N. Sarkaria	2014	57
15	Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts Clinical Cancer Research ·Gaspar J. Kitange,Ann C. Mladek,Brett L. Carlson,Mark A. Schroeder,Jenny L. Pokorny,Ling Cen,Paul A. Decker,Wenting Wu,Gwen Lomberk,Shiv K. Gupta,Raúl Urrutia,Jann N. Sarkaria	2012	125
16	Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients Journal of Clinical Investigation ·Sameer Agnihotri,Aaron S. Gajadhar,行信杉村,Thierry Gorlia,Kristin Diefes,Paul S. Mischel,Joanna Kelly,Gail McGown,Mary Thorncroft,Brett L. Carlson,Jann N. Sarkaria,Geoffrey P. Margison,Kenneth Aldape,Cynthia Hawkins,Monika E. Hegi,Abhijit Guha	2011	137
17	Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance Journal of Neuro-Oncology ·Gaspar J. Kitange,Brett L. Carlson,Mark A. Schroeder,Paul A. Decker,Bruce W. Morlan,Wenting Wu,Karla V. Ballman,Caterina Giannini,Jann N. Sarkaria	2010	43
18	Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts Neuro-Oncology ·Gaspar J. Kitange,Brett L. Carlson,Mark A. Schroeder,Patrick T. Grogan,純敬税所,Paul A. Decker,Wenting Wu,C. David James,Jann N. Sarkaria	2008	297
19	An ergonomic evaluation of nursing assistants' job in a nursing home Ergonomics ·A Garg,Bernice D. Owen,Brett L. Carlson	1992	138
20	Continuous exposure of HeLa cells to caffeine Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis ·Philip S. Thayer,S. Yang,Robert H. Liss,Brett L. Carlson	1971	11

About Brett L. Carlson

Brett L. Carlson is a scholar working on Genetics, Oncology and Biotechnology, having authored 69 papers that have together received 3.6k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (46 papers), DNA Repair Mechanisms (12 papers), Brain Metastases and Treatment (10 papers), Cancer-related Molecular Pathways (10 papers), PARP inhibition in cancer therapy (9 papers), Cancer Research and Treatments (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Microtubule and mitosis dynamics (6 papers). The work is most often cited by research in Genetics (1.4k citations), Cancer Research (725 citations) and Oncology (1.3k citations). Brett L. Carlson has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Jann N. Sarkaria, Mark A. Schroeder, C. David James, Paul A. Decker, Gaspar J. Kitange, Wenting Wu, Caterina Giannini, Ann C. Mladek, Patrick T. Grogan and Jenny L. Pokorny. Their work appears in journals such as Neuro-Oncology, Clinical Cancer Research, Cancer Research, Molecular Cancer Therapeutics and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact